{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:30:06Z","timestamp":1768005006532,"version":"3.49.0"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"S3","license":[{"start":{"date-parts":[[2003,12,1]],"date-time":"2003-12-01T00:00:00Z","timestamp":1070236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2003,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Learning Objectives<\/jats:title>\n                  <jats:p>After completing this course, the reader will be able to:<\/jats:p>\n                  <jats:p>Discuss the current issues surrounding the treatment of multiple myeloma. Describe how treatment modifications have improved the tolerability and efficacy of this multiple myeloma therapy. Explain recent treatment advances in this disease.<\/jats:p>\n                  <jats:p>Access and take the CME test online and receive one hour of AMA PRA category 1 credit at CME.TheOncologist.com<\/jats:p>\n                  <jats:p>The combination of vincristine, doxorubicin, and dexamethasone is an effective treatment for multiple myeloma that produces a more rapid response than other regimens, probably a function of the high-dose, intense steroid schedule. However, vincristine\/doxorubicin\/dexamethasone administration requires a 96-hour continuous infusion delivered via a central venous catheter, which necessitates hospitalization in a large number of patients and may increase the risk for infection. Moreover, the high dosages of corticosteroids required with this regimen can cause substantial toxicity. Therefore, a number of modifications to the regimen have been evaluated in an effort to improve its tolerability and efficacy. These include replacing doxorubicin with pegylated liposomal doxorubicin and using a reduced frequency of dexamethasone, and, later, the addition of thalidomide. The results of an ongoing study demonstrated that this latest regimen (including thalidomide) is associated with an improved response rate and a higher quality of response compared with previous regimens in patients with relapsed\/refractory multiple myeloma. This modified regimen is well tolerated when prophylactic and supportive measures are incorporated. Although additional follow-up is required to determine the effect on survival, this modified regimen has significant potential in the management of advanced myeloma.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.8-suppl_3-39","type":"journal-article","created":{"date-parts":[[2004,8,25]],"date-time":"2004-08-25T16:31:55Z","timestamp":1093451515000},"page":"39-45","source":"Crossref","is-referenced-by-count":29,"title":["Modifications to Therapy for Multiple Myeloma: Pegylated Liposomal Doxorubicin in Combination With Vincristine, Reduced-Dose Dexamethasone, and Thalidomide"],"prefix":"10.1093","volume":"8","author":[{"given":"Mohamad A.","family":"Hussein","sequence":"first","affiliation":[{"name":"Cleveland Clinic Myeloma Research Program, Cleveland, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2003,12,1]]},"reference":[{"key":"2021122209451664000_R1","first-page":"2465","volume-title":"Principles and Practice of Oncology, Volume 2","author":"Munshi","year":"2001","edition":"Sixth Edition"},{"key":"2021122209451664000_R2","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/ajh.2830330203","article-title":"VAD-based regimens as primary treatment for multiple myeloma","volume":"33","author":"Alexanian","year":"1990","journal-title":"Am J Hematol"},{"key":"2021122209451664000_R3","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S0140-6736(89)91549-3","article-title":"Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma","volume":"2","author":"Samson","year":"1989","journal-title":"Lancet"},{"key":"2021122209451664000_R4","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJM198405243102104","article-title":"Effective treatment of advanced multiple myeloma refractory to alkylating agents","volume":"310","author":"Barlogie","year":"1984","journal-title":"N Engl J Med"},{"issue":"suppl 10","key":"2021122209451664000_R5","first-page":"309b","article-title":"Melphalan-prednisone versus dexamethasone-based regimens for newly diagnosed myeloma patients aged 65\u201375 years. Safety analysis of the IFM 95 trial on 457 patients [abstract]","volume":"94","author":"Facon","year":"1999","journal-title":"Blood"},{"key":"2021122209451664000_R6","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.2165\/00003495-200262140-00012","article-title":"Polyethylene-glycol-liposomal doxorubicin: a review of its use in the management of solid and haematological malignancies and AIDS-related Kaposi's sarcoma","volume":"62","author":"Sharpe","year":"2002","journal-title":"Drugs"},{"key":"2021122209451664000_R7","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1002\/cncr.10946","article-title":"A phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients","volume":"95","author":"Hussein","year":"2002","journal-title":"Cancer"},{"key":"2021122209451664000_R8","first-page":"403a","article-title":"Doxil (D), vincristine (V), decadron (d) and thalidomide (T) (DVd-T) for relapsed\/refractory multiple myeloma (RMM) [abstract]","volume":"100","author":"Hussein","year":"2002","journal-title":"Blood"},{"key":"2021122209451664000_R9","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1081\/CNV-100103136","article-title":"Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy","volume":"19","author":"Gabizon","year":"2001","journal-title":"Cancer Invest"},{"key":"2021122209451664000_R10","volume-title":"Doxil\u00ae (doxorubicin HCl liposome injection). Prescribing Information","year":"2000"},{"key":"2021122209451664000_R11","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/sj.bjc.6690070","article-title":"Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma","volume":"79","author":"Ribatti","year":"1999","journal-title":"Br J Cancer"},{"key":"2021122209451664000_R12","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1365-2141.1994.tb08304.x","article-title":"Bone marrow angiogenesis and progression in multiple myeloma","volume":"87","author":"Vacca","year":"1994","journal-title":"Br J Haematol"},{"key":"2021122209451664000_R13","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1023\/A:1008216430806","article-title":"The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin","volume":"9","author":"Berry","year":"1998","journal-title":"Ann Oncol"},{"key":"2021122209451664000_R14","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1023\/A:1008365716693","article-title":"Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg\/m2","volume":"11","author":"Safra","year":"2000","journal-title":"Ann Oncol"},{"key":"2021122209451664000_R15","first-page":"45a","article-title":"Reduced cardiac toxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin (Caelyx\/Doxil) vs","volume":"21","author":"Wigler","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"suppl 111","key":"2021122209451664000_R16","first-page":"165a","article-title":"Prospective randomized comparison of VAD administered as intravenous bolus injection and of VAD with liposomal doxorubicin (Doxil) as first line treatment in multiple myeloma [abstract]","volume":"98","author":"Dimopoulos","year":"2001","journal-title":"Blood"},{"issue":"suppl 11","key":"2021122209451664000_R17","first-page":"308b","article-title":"Phase I\/II study with liposomal-encapsulated doxorubicin in VAD-protocol for patients mit [sic] multiple myeloma [abstract]","volume":"98","author":"Dingeldein","year":"2001","journal-title":"Blood"},{"key":"2021122209451664000_R18","first-page":"28a","article-title":"Doxil, vincristine and dexamethasone: a new regimen for elderly patients with multiple myeloma [abstract]","volume":"18","author":"Gautier","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122209451664000_R19","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1034\/j.1600-0609.2000.90145.x","article-title":"Administration of a modified chemotherapeutic regimen containing vincristine, liposomal doxorubicin and dexamethasone to multiple myeloma patients: preliminary data","volume":"65","author":"Tsiara","year":"2000","journal-title":"Eur J Haematol"},{"key":"2021122209451664000_R20","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/j.1365-2141.1992.tb06466.x","article-title":"Modified adriamycin-vincristine-dexamethasone (m-VAD) in primary refractory and relapsed plasma cell myeloma: an NCI (Canada) pilot study","volume":"82","author":"Browman","year":"1992","journal-title":"Br J Haematol"},{"key":"2021122209451664000_R21","article-title":"A phase III randomized trial of Doxil\u00ae\/CAELYX\u2122, vincristine, and dexamethasone (DVd) versus vincristine, Adriamycin\u00ae, and reduced-dose dexamethasone (VAd) in the treatment of patients with newly diagnosed multiple myeloma (n-MM) [poster]","volume-title":"Presented at the 38th Annual Meeting of the American Society of Clinical Oncology","author":"Hussein","year":"2002"},{"key":"2021122209451664000_R22","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2165\/00002512-200219020-00002","article-title":"Thalidomide in cancer treatment: a potential role in the elderly?","volume":"19","author":"Zhou","year":"2002","journal-title":"Drugs Aging"},{"key":"2021122209451664000_R23","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1056\/NEJM199911183412110","article-title":"Thalidomide\u2014a revival story [editorial]","volume":"341","author":"Raje","year":"1999","journal-title":"N Engl J Med"},{"key":"2021122209451664000_R24","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2003.03.139","article-title":"Thalidomide alone or with dexamethasone for previously untreated multiple myeloma","volume":"21","author":"Weber","year":"2003","journal-title":"J Clin Oncol"},{"key":"2021122209451664000_R25","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1200\/JCO.2002.02.116","article-title":"Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma","volume":"20","author":"Rajkumar","year":"2002","journal-title":"J Clin Oncol"},{"key":"2021122209451664000_R26","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/sj.thj.6200150","article-title":"The combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is feasible and can be an option for relapsed\/refractory multiple myeloma","volume":"3","author":"Garcia-Sanz","year":"2002","journal-title":"Hematol J"},{"key":"2021122209451664000_R27","first-page":"276a","article-title":"Slow incremental dosing of thalidomide improves tolerance and duration of therapy in myeloma patients [abstract]","volume":"21","author":"Farray","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122209451664000_R28","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1046\/j.1365-2141.2001.02715.x","article-title":"Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma","volume":"113","author":"Dammacco","year":"2001","journal-title":"Br J Haematol"},{"key":"2021122209451664000_R29","doi-asserted-by":"crossref","first-page":"10526","DOI":"10.1073\/pnas.97.19.10526","article-title":"Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury","volume":"97","author":"Brines","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021122209451664000_R30","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1073\/pnas.95.8.4635","article-title":"In vivo evidence that erythropoietin protects neurons from ischemic damage","volume":"95","author":"Sakanaka","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021122209451664000_R31","first-page":"1565","article-title":"Deep venous thrombosis and thalidomide therapy for multiple myeloma","volume":"341","author":"Osman","year":"1999","journal-title":"N Engl J Med"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.8-suppl_3-39","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.8-suppl_3-39","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/8\/S3\/39\/41840088\/oncolo_8_s3_39.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/8\/S3\/39\/41840088\/oncolo_8_s3_39.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T17:13:28Z","timestamp":1640193208000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/8\/S3\/39\/6387544"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,12,1]]},"references-count":31,"journal-issue":{"issue":"S3","published-online":{"date-parts":[[2003,12,1]]},"published-print":{"date-parts":[[2003,12,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.8-suppl_3-39","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2003,12,1]]},"published":{"date-parts":[[2003,12,1]]}}}